Sep 10, 2019 / 02:00PM GMT
Rivka Regina Goldwasser - Morgan Stanley, Research Division - MD
Good morning, everybody. It is my pleasure to introduce our next guest for the day.
To my left is Jim Foster, CEO of Charles River. I think you all know Charles River is a contract research organization and really a market leader in the preclinical segment.
And Jim, when we think about your business, you have a very broad scope of portfolio: Toxicology, animal model, discovery. And you've -- in a great position and have been to really benefit from the increased biopharma spend. So with that in mind, you can take a few minutes just to help frame the conversation for us and just kind of like walk us through what are you seeing in the overall market?
James C. Foster - Charles River Laboratories International, Inc. - Chairman, CEO & President
Yes. I would say that biotech has been a principal driver of our growth for probably 5 or 6 years now. And I don't really know when the crossover was, but we were always the supplier to pharma. And I'd say 8 or 9 years ago, biotech sort of
Charles River Laboratories International Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers